5MO Effect of amivantamab dose interruptions on efficacy and safety of first-line amivantamab plus lazertinib in EGFR-mutant advanced NSCLC: Exploratory analyses from the MARIPOSA study

M.R. García Campelo,B.C. Cho, N. Girard, S. Lu, H. Yoshioka, J-S. Lee,S-H. Lee, B. Liu, M.A.N. Sendur, B. Besse, A. Spira, E. Felip, A. Aguilar, J. Sabari, S. Popat, P. Mahadevia, S. Sethi, J.M. Bauml, Y.V. Ostapenko

ESMO Open（2024）

引用 0|浏览0